Chong O. Lee

Daejeon, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Novel brd4 inhibitors with a unique scaffold exhibit antitumor effects.

Novel brd4 inhibitors with a unique scaffold exhibit antitumor effects.

Journal: Oncology letters

Published: August 10, 2020

Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras.

Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras.

Journal: European journal of medicinal chemistry

Published: May 14, 2020

Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).

Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).

Journal: Biochemical and biophysical research communications

Published: September 17, 2018

A natural compound, aristoyagonine, is identified as a potent bromodomain inhibitor by mid-throughput screening.

A natural compound, aristoyagonine, is identified as a potent bromodomain inhibitor by mid-throughput screening.

Journal: Biochemical and biophysical research communications

Published: June 11, 2018

Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.

Folate receptor 1 (FOLR1) targeted chimeric antigen receptor (CAR) T cells for the treatment of gastric cancer.

Journal: PloS one

Published: February 21, 2018

Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors.

Synthesis and biological evaluation of indazole-4,7-dione derivatives as novel BRD4 inhibitors.

Journal: Archives of pharmacal research

Published: August 11, 2017

Corrigendum to "Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors" [Bioorg. Med. Chem. Lett. 24 (2014) 5093-5097].

Corrigendum to "Discovery of substituted 6-pheny-3H-pyridazin-3-one derivatives as novel c-Met kinase inhibitors" [Bioorg. Med. Chem. Lett. 24 (2014) 5093-5097].

Journal: Bioorganic & medicinal chemistry letters

Published: May 29, 2017

Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor.

Novel 2,4-diaminopyrimidines bearing fused tricyclic ring moiety for anaplastic lymphoma kinase (ALK) inhibitor.

Journal: Bioorganic & medicinal chemistry letters

Published: January 23, 2017

Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R.

Replacing the terminal piperidine in ceritinib with aliphatic amines confers activities against crizotinib-resistant mutants including G1202R.

Journal: European journal of medicinal chemistry

Published: August 24, 2016

Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer.

Minor modifications to ceritinib enhance anti-tumor activity in EML4-ALK positive cancer.

Journal: Cancer letters

Published: December 22, 2015

Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies.

Novel 2,4-diaminopyrimidines bearing tetrahydronaphthalenyl moiety against anaplastic lymphoma kinase (ALK): Synthesis, in vitro, ex vivo, and in vivo efficacy studies.

Journal: Bioorganic & medicinal chemistry letters

Published: October 26, 2015

Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors.

Discovery of novel tetrahydroisoquinoline-containing pyrimidines as ALK inhibitors.

Journal: Bioorganic & medicinal chemistry

Published: October 08, 2015

Showing 1-12 of 22

Last Updated: 09/26/2026